Introduction
B cell chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in Western countries and represents 30% of all leukemic cases. 1 Previous studies on ethnic distribution of CLL in the world have shown considerable variations.
A high incidence of CLL in the United Kingdom, Connecticut, Minnesota and Eastern Europe has been reported. 2, 3 In Japan, Korea, Singapore, Kuwait and Mexico the disease is significantly less common. [4] [5] [6] [7] [8] The incidence of CLL remains low in US Asians and among Japanese who have immigrated to Hawaii which emphasizes racial and/or hereditary factors in the occurrence of this malignant disease. 9, 10 CLL was reported to occur frequently in the Jewish population of Brooklyn, NY. 11 In Israel, the survey of 288 cases of CLL in 1978 has shown that 80% of these individuals originated from the European countries (Ashkenazi Jews), whereas only 15% descended from Asia and Africa (Sephardic Jews). 12 The impact of ethnic origin of the patients on the pattern and prog-nosis of CLL is unknown. Our present study deals with a series of 302 B cell CLL and prolymphocytic leukemia (PLL) cases, originating from Eastern Europe, Asia and Africa, followed for up to 20 years in a Southern area of Israel. Clinical pattern, biological parameters, prognosis and outcome were investigated and compared in both ethnical groups.
Materials and methods

Epidemiological research
Our study deals with 302 cases of CLL and related B cell disorders, which were recruited during 1975-1996 in a single center covering the Hashfela region -a Southern area of Israel with a current population of approximately 430 000 inhabitants. Eleven additional patients arrived in Israel with CLL already diagnosed and are not included in this analysis. Due to the natural demographic increase and immigration the population of this region doubled in the period reviewed. There was a prevalence of Asian and African Jews in 1970-1980s in this region compared to Ashkenazi (standardized Sephardic/Ashkenazi ratio 1:1.54) but after an immigration wave during 1989-1996 from the former USSR, which brought with it approximately 60 000 new inhabitants, the ethnic distribution of the population is almost equal (standardized Sephardic/Ashkenazi ratio 1:1.03). Demographic data were taken from the Central Bureau of Statistics, Jerusalem. 13 
Patients
The B-CLL-diagnosis was made according to standard clinical, cytological and immunological parameters. The clinical characteristics examined were origin, sex, age, presence of lymphadenopathy and splenomegaly at diagnosis, Rai stage at presentation, progression and duration of the disease and associated diagnoses. The laboratory studies analyzed were level of hemoglobin, white blood and lymphocyte count, platelets, total protein, globulin, serum immunoglobulin, ␤2-microglobulin and complement (C3, C4) level, direct Coombs test, presence of rheumatoid (RF) and antinuclear factor (ANF). The existence of monoclonal proteins in patients' serum was determined by electrophoresis on cellulose acetate.
Cases were classified according to the modified FAB criteria: (1) typical CLL (Ͼ90% small lymphocytes, Ͻ10% prolymphocytes, Ͻ10% large lymphocytes); (2) PLL (Ͼ55% prolymphocytes forms); (3) atypical CLL, including cases with Ͻ90% small lymphocytes and Ͻ55% prolymphocytes (CLL/PL) and some cases with atypical lymphocyte morphology: cleaved cell nucleus or multiple intracytoplasmatic vacuoles.
Immunophenotyping study
Immunophenotyping was performed on blood mononuclear cells by indirect immunofluorescence with a panel of MoAbs. The MoAbs used were anticlass II HLA-DR (Ia), CD19, CD20,  CD3, CD4, CD8, CD5, CD10, CD38, CD71 , IgM, IgD, IgG, IgA, kappa and lambda (Coulter Immunology, Hialeah, FL, USA). The cells were tested also for FMC7 antigen (Sera-lab, Sussex, UK) and for RAB1 -a MoAb directed against hairy cell leukemia and defining activation antigens.
14 Thirty per cent or more cells expressing antigen were considered as positive. Only CD5-positive CLL cases were eligible for the study.
Immunoglobulin heavy chain rearrangement
A study for immunoglobulin heavy chain rearrangement was undertaken in 14 patients in various stages of CLL: seven Ashkenazi cases (three cases in Rai stage 0-1 and four cases in 3-4 stage) and seven cases from the Sephardic group (two 'early' and five advanced stage). DNA extracted from peripheral blood cells was digested with the restriction endonuclease HindIII, hybridized to 32 P-labeled gene probes and studied autoradiographically as described previously. 15 
Statistical methods
Statistical Analysis System (SAS Institute, Cary, NC, USA) software was used for the basic analysis. Stata (Stata Corporation, University Drive East, TX, USA) was used for personyear calculation and estimation of disease incidence. Estimation of person-year was made on the basis of the annual population of Israel divided by sex and age group. Census in stratifying age was according to 5-year intervals for each ethnic group. Age-adjusted rates were calculated on standard world population. Relative risk (RR) was estimated on the Poisson model with adjustment for years of diagnosis, age and sex. Survival analysis was made using a Kaplan-Meier estimation. Comparisons of survival rates for clinical groups was made using the Wilcoxon sum test. Percentage distribution of CLL cases by period of diagnosis and duration of stay in Israel has been calculated according to 7 year intervals.
Results
Incidence of CLL
Three hundred and two cases were included in the present study: 172 male and 130 female. The distribution of the patients revealed that 207 were Ashkenazi Jews (68.5%) and 95 (31.5%) were Sephardic Jews. In the Ashkenazi group 151 (72.9%) were typical CLL, 30 (14.5%) atypical CLL and 26 (12.6%) PLL. In the Sephardic patients distribution showed 65 (68.4%), 15 (15.8%) and 15 cases (15.8%), respectively (Table  1) . No significant differences were found in patients' age at diagnosis in all clinical groups. A mild female predominance was seen only in Ashkenazies suffering from PLL. There was no significant difference in distribution of clinical subtypes between the two ethnic groups.
The mean annual age-adjusted incidence in 1975-1979 was 2.5 cases per 100 000 person-year, in 1980-1989 3.0, and in the period 1990-1996 4.3 cases per 100 000 personyear ( Table 2 ). The incidence of CLL was significantly higher in Ashkenazi Jews (RR = 3.3, P Ͻ 0.01) ( Figure 1 ). The relative risk for Ashkenazies compared to Sephardies was 6.0 in the 1975-1979 period, 2.2 in 1980-1989, and 2.4 in 1990-1996. Linear increase in CLL incidence was observed during the period reviewed (RR = 0.07, P Ͻ 0.01). Stratified by ethnical origin, analysis showed that CLL incidence increased (RR = 0.15, P Ͻ 0.01) with years of diagnosis in the Sephardic group with no statistically significant trend in Ashkenazies. Figure 2 describes the distribution of the patients according to country of origin, showing an obvious predominance of patients originating from Russia and other Eastern European countries. It is remarkable that 26 out of 101 Ashkenazi CLL cases diagnosed in the period 1989-1996 were found in new immigrants from the former USSR, while an additional 11 patients not included in this analysis arrived in the same period in Israel with diagnosis already made. Table 3 relates to distribution of CLL cases according to the period of diagnosis and duration of stay in Israel. Two significant values can be emphasized: a transient increase of Ashkenazi cases diagnosed in the first 10 years after arrival in Israel, but later between 30 and 39 years of stay we found a significant increase in new Sephardic patients diagnosed (P Ͻ 0.05).
The mean annual age-adjusted incidence of PLL in the observed period was 0.9 per 100 000 person-year. In the Ashkenazi group the PLL incidence was 1.1 and in Sephardics 0.6 cases per 100 000 person-year. This difference was not significant.
Patient characteristics
Most of the patients with typical CLL at time of diagnosis were found in the early stage of the disease, 80% at presentation were in 0-1 Rai stage and less than 10% of patients were diagnosed in 3-4 Rai stage (Table 1) . No differences in the presence of lymphadenopathy or splenomegaly in ethnic groups were seen. A proportion of cases in an advanced stage of the disease was higher in both ethnic groups in atypical disease -20% of the patients were in 3-4 Rai stages. The percentage of all patients diagnosed at early stages (Rai 0-1) increased during the decade 1986-1996 (79%) compared to the period 1975-1985 (70%).
Laboratory characteristics (level of hemoglobin, white blood and lymphocyte count, platelets, total protein, globulin, serum immunoglobulin, ␤2-microglobulin and complement (C3, C4) levels, positivity for direct Coombs test, RF, ANF, monoclonal proteins) revealed no significant differences in all parameters analyzed. B cell markers Ia, CD5, CD20, CD19 were expressed equally in both ethnic CLL groups as well as weak surface immunoglobulin (SIg).
A similar expression of activation antigens CD10, CD38, PCA1, FAB7, RAB1, CD71 and strong SIg was seen in most PLL cases of both ethnic groups.
Study of immunoglobulin heavy chain rearrangements showed several patterns of JH band hybridization. A germline band was demonstrated in the DNA of 10 out of 14 cases. In 12 of the samples additional bands were observed varying from one to four bands. No significant differences were detected in the early stages but this preliminary report showed more aberrations in advanced stages of CLL in Ashkenazies, including absence of germline in 2/4 patients, and more cases showed multiple hybridizing bands while in two out of five Sephardic cases with advanced disease no rearrangement was found. 
Figure 1
Incidence of CLL in Ashkenazi and Sephardic Jews. 
Clinical course
Progression of the disease was noted in 40% of all typical CLL cases, 75% of atypical CLL cases and more than 90% in PLL (Table 4) . A small proportion of CLL (12% of the cases) transformed to more aggressive diseases -Richter's syndrome or prolymphocytoid type. The proportion of progressed and transformed cases was similar in individuals originating from Europe-America and Asia-Africa. Secondary malignant tumor was observed at presentation or during follow-up in 31 patients. The most frequent tumors associated with CLL were skin neoplasm (16 cases), tumor of genitourinary system (12 cases), respiratory tract (four cases) and other hematological malignancies (seven cases). Autoimmune hemolytic anemia (AIHA) was observed in 18 CLL and in one PLL case of the European group, and in six CLL and one PLL of the Sephardic group. The other immune syndromes encountered were immune thrombocytopenia (ITP), three; pure red cell aplasia, three; Evan's syndrome, two; vasculitis, six; rheumatoid arthritis, five; and Sjogren's syndrome, nine cases. The occurrence of secondary neoplasm or autoimmune complications did not show remarkable differences between the two ethnic groups.
At the time of this report 170 patients from 284 followed are still alive and 114 have died. The principal cause of death was progression of the disease, especially in PLL. Thirty patients died from infection without progression of the disease (seven cases) or from cases not related to CLL: cardio-vascular accident, 20 cases; metastatic carcinoma, one; suicide, one; and colon perforation, one ( Table 5) .
The median survival in Ashkenazies with typical CLL was 120 months and in Sephardies 137 months. The patients with the atypical form of CLL and PLL had a significantly poorer survival (P Ͻ 0.001). The median survival in Ashkenazies with atypical CLL was 65 months, in Sephardies 43; in PLL 70 months and 61 months, respectively. There was no significant difference in survival rate of patients with identical disease subtype between the two ethnic groups (P = 0.89).
Discussion
The results of the present study show a high incidence of CLL and related diseases in the Hashfela region of Israel which has approximately 430 000 inhabitants. The mean age-adjusted incidence of CLL 4.3 per 100 000 person-year is among the highest reported values. A high incidence of CLL in Israel and a striking prevalence of CLL in Jews born in European-American countries (Ashkenazi Jews) in comparison to those originating from Asia and Africa (Sephardic Jews) has been reported previously. 12, 19 This present study confirms the prevalence of CLL in Jews born in Europe and America. The majority of our CLL patients originated from Eastern Europeformer USSR, Poland, Romania. Interestingly, the new immigration of Russian Jews brought 37 new cases in the last 8 years (11 already diagnosed), while no cases of CLL were found in approximately 10 000 Ethiopian immigrants who settled in our region. The incidence rate in new immigrants from the former USSR was slightly higher than that in the total Ashkenazi population. However, the previously described ratio of 4:1 between Ashkenazi and Sephardic Jews in Israel 12 tends to decrease to 2.4:1. While the incidence rate showed only a slight increase during the period of 1975-1996 in the Ashkenazi group, Sephardics, who initially exhibited a low risk, appeared to acquire rather higher rates after migration. We showed that in a period of stay in Israel of less than 10 years, more CLL cases were diagnosed in Ashkenazi Jews. This finding is probably due to the higher risk among Russian Jews and not to the older age of the immigrant population. According to data from the Central Bureau of Statistics, we did not find a higher percentage of elderly immigrants (12.6% Ͼ65 years old). Later (more than 20 years duration of stay) increase in incidence is more prominent in the Sephardic group. We believe that the increase of CLL risk in both population groups is due to older age since CLL is more frequent among the elderly. In addition, the increased number of CLL in Asian and African-born patients in the 1960s-1990s was possibly due to improved health care access in this group of the population as well as an increase in the number of routine analyses performed. We found that the percentage of CLL patients diagnosed at early stages (Rai 0-1) increased in the last decade. However, these results may also suggest that African-Asian-born individuals underwent changes due most probably to environmental exposure (dietary, professional, pollution, etc) which gave rise to a substantial increase in CLL risk during their lifespan. Environmental factors (rural areas) 20 and occupational exposure (pesticides used by farmers) 21, 22 have been suggested as playing a role in the etiology of CLL. Steinitz et al 19 who studied the cancer incidence in Jewish migrants to Israel between 1961 and 1981, hypothesized that variation in incidence for Jews originating from different countries is often very large and may reflect the pattern of incidence in countries of origin, differences in susceptibility to cancer and other unexplained causes. The relative importance of environmental exposure vs inherited predisposition to CLL remains to be determined. Familial aggregation of cases in first-degree relatives of CLL patients has occasionally been reported 23, 24 suggesting an impact of genetic factors on the disease development. Iscovich and Parkin 25 reported an analysis on the risk of lymphomas and leukemias in the population under 30 years old in Israel, which has a low CLL incidence in this age. However, they found more non-Hodgkin's lymphomas in immigrants from Asia and Africa and their offspring. The impact of genetic, geographic and ethnic factors on the clinical picture and survival in all cancers, including leukemias, has been demonstrated previously. [26] [27] [28] CLL is a rare type of leukemia in Asia and Africa, including China, Saudi-Arabia and Jordan. [4] [5] [6] [7] 18, [29] [30] [31] [32] [33] In Japan, where CLL is rare, most clinical and laboratory features do not differ from those of Western countries, showing a similar incidence and pattern of cytogenetic aberrations and rearrangement of the bcl-2 and bcl-3 genes. 34 We do not have sufficient data on the exact incidence and epidemiology of CLL in the Mediterranean countries and Eastern Europe; however, an obvious predominance of the disease in the Jewish population has been mentioned occasionally. 35 Studies of cancer in migrant populations may be useful to evaluate the relationship between changes in exposure to various environmental agents and changes in the disease risk. The Israeli population provides obvious tools to study cancer risk in relation to environmental factors in migrants. It has been shown, for example, that an apparent increase in colorectal cancer incidence is related to the period of stay of all migrant populations. Interesting changes have been encountered also in intestinal lymphoma, common in Mediterranean countries and the Middle East but tending to decline in Israel. Changes in risk in relation to length of time in the new environment have been described clearly in malignant melanoma with an incidence five times greater in European Jews than the AfroAsian population. 19 Dietary factors such as fat and protein consumption which changed in migrants are also suspected of being important in cancer site and etiology. 36 As seen in Figure 2 , our Sephardic patients originated from North Africa, Yemen, Iraq, Iran, where the diet is rich in carbohydrates, and the changes in their diet included more proteins and fat. 37 The influence of diet on the occurrence of CLL remains to be determined.
The present study was undertaken in order to compare clinical, biological, cytological, immunological characteristics in CLL and B cell-related diseases in Ashkenazi and Sephardic Jews in Israel. Three hundred and two cases were identified: 172 male and 130 female. Cases included typical CLL, atypical CD5-positive form of the disease and PLL. Clinical parameters at the time of diagnosis were comparable in both ethnic groups. A nonsignificant prevalence of Ashkenazi females was noted in PLL, the mean age and gender ratio of patients was equal. No differences in the incidence of lymphadenopathy and splenomegaly were found. Laboratory parameters and immunological markers did not differ. Most CLL patients at presentation were in the early stages of the disease. The follow-up showed a similar pattern and rate of disease progression. Survival curves were dependent on disease subtype but not on the ethnic origin of the patients.
In conclusion, we found that the ethnic origin (Ashkenazi/Sephardic) influenced differences in the morbidity rate of CLL in Israel. Environment, changes in diet and better access to health care (migrant effects) may explain changes in CLL incidence seen in the Afro-Asian group. The ethnic origin by itself does not seem to affect the biological and clinical behavior of this disease.
